l -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

• DOI: 10.1212/wnl.0b013e3182a351fb
• Publication Date: 2013-08-08T01:58:49Z
• Authors: Nicholas Schwab; Tilman Schneider-...; Vilmos Posevitz; Johanna Breuer; Kerstin Göbel; Susanne Windhagen; Bruno Brochet; Patrick Vermersch; Christine Lebrun-...; Anita Posevitz-Fe...; Ruggero Capra; Luisa Imberti; Vera Straeten; Juergen Haas; Brigitte Wildemann; Joachim Havla; Tania Kümpfel; Ingrid Meinl; Kyle Niessen; Susan Goelz; Christoph Kleinsc...; Clemens Warnke; Dorothea Buck; Ralf Gold; Bernd C. Kieseier; Sven G. Meuth; John Foley; Andrew Chan; David Brassat; Heinz Wiendl
• Keywords: Natalizumab

To find biomarkers identifying patients at risk for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment.Patients were recruited from 10 European and US cohorts. Of 289 with multiple sclerosis (MS), 224 had been treated (18-80 months), 21 received other immune-modulatory treatments, 28 untreated. We access to samples 16 PML patients. Eight these given blood before diagnosis PML. also analyzed non-natalizumab-treated who developed (n = 10) age- sex-matched healthy donors 31). All flow cytometric assessments done on previously cryopreserved, viable peripheral mononuclear cells.The percentage l-selectin-expressing CD4+ T cells was significantly lower in long-term (40.2%) when compared not receiving treatment (47.2%; p 0.016) or controls (61.0%; < 0.0001). An unusually low (9-fold lower; 4.6%) highly correlated developing patient group available pre-PML non-PML natalizumab-treated (p ≤ Samples gathered between 4 26 months diagnosis.The cell-based assessment CD4 could provide an urgently needed biomarker individual assessment.